Absci Corporation
ABSI
$0.01
Change (1 day)
$6.72
Year High
$1.35
Year Low
Categories
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
P/E ratio for Absci Corporation (ABSI)
P/E ratio as of 2023: -3.50
According to Absci Corporation's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.50. At the end of 2022 the company had a P/E ratio of -1.82.
P/E ratio history for Absci Corporation from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.50 |
| 2022 | -1.82 |
| 2021 | -7.52 |
| 2020 | -136.71 |
| 2019 | -292.85 |